Several rare primary lung neoplasms may present as multiple synchronous indeterminate lung nodules on chest CT. These merit increased awareness among radiologists, pathologists and pulmonologists, as well as a multidisciplinary team approach.

Cite this article as: Ghosh S, Mehta AC, Abuqayyas S, et al. Primary lung neoplasms presenting as multiple synchronous lung nodules. Eur Respir Rev 2020; 29: 190142 [https://doi.org/10.1183/16000617.0142-2019].
literature to guide treatment contribute to the lack of awareness among physicians. We rationalise that this review will increase awareness of this group of rare entities, encourage the need for discussion in a multidisciplinary setting, help expedite the diagnostic process and prompt appropriate management. We have intentionally excluded deposition diseases such as amyloidosis, which can also manifest as multiple bilateral lung nodules but are considered non-neoplastic. A classification system based on the cell of origin of these rare tumours is depicted in table 1.

**Lymphoproliferative disorders**

Primary pulmonary lymphomas are rare neoplasms compromising <1% of all non-Hodgkin lymphomas and 0.5–1% of all primary pulmonary malignancies. They include pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT) lymphomatoid granulomatosis, post-transplant lymphoproliferative disorder (PTLD) and diffuse large B-cell lymphoma (DLBCL) [1].

**Pulmonary extranodal marginal zone lymphoma of MALT**

MALT lymphoma, which makes up approximately 70–90% of the primary pulmonary lymphomas, is considered an indolent neoplasm with a potential for slow growth and dissemination over a prolonged period of time. It has a slight female predominance [2, 3] and a favourable prognosis with a 2-year survival of 100% and a 5-year survival close to 80% [4–11]. The median (range) age at the time of diagnosis is 61 (range: 21–80) years, and over half of patients are smokers. Many patients present with an asymptomatic mass on imaging studies. When present, symptoms include cough, minor dyspnoea, night sweats, weight loss, chest pain and, rarely, haemoptysis [12].

Pulmonary MALT lymphomas have an association with smoking [13] and disease states characterised by chronic lung inflammation, such as hypersensitivity pneumonitis, diffuse panbronchiolitis and rheumatoid arthritis [14–17], supporting a theory of antigenic stimulation resulting in bronchial lymphoid tissue proliferation.

Multiple unilateral or bilateral pulmonary nodules, lung masses and/or airspace consolidation are the most common CT imaging features in up to 70% of patients (figure 1). There may be associated peribronchial thickening and air bronchograms with bronchial distension. Lymphangitic spread into the surrounding parenchyma and hilum, as well as mediastinal lymphadenopathy, are other imaging features that may be seen. Rarely, cystic lesions or pleural effusions are reported [6, 7, 18].

The diagnosis is made by histological examination of specimens obtained from surgical biopsies – either thoracotomy or video-assisted thoracoscopy. Transbronchial biopsies have a significantly lower yield. Morphological features include the presence of lymphocytes with proliferation around the bronchovascular interstitium and subpleural areas (figure 2a). Invasion into the bronchioles, vessels and pleura is a common finding that distinguishes MALT lymphomas from exuberant reactive infiltrates (figure 2b). The infiltrate is comprised of diffuse, small lymphocytes, plasmacytoid lymphocytes, so-called centrocyte-like B-cells and monocytoid B-cells (figure 2c). These cells may overrun adjacent reactive follicles, so-called follicular colonisation. Immunohistochemical staining reveals a predominance of CD20⁺ lymphocytes

| TABLE 1 Classification system based on the cells of origin of multiple synchronous lung nodules |
|-------------------------------------------------|
| **Lymphoproliferative disorders**                |
| - MALT lymphoma                                 |
| - Lymphomatoid granulomatosis                   |
| - Post-transplant lymphoproliferative disorder  |
| - Diffuse large B-cell lymphoma                 |
| **Vascular tumours**                            |
| - Epithelioid haemangiendothelioma               |
| - Kaposi’s sarcoma                              |
| - Angiosarcoma                                  |
| **Neuroendocrine cell line**                    |
| - Diffuse idiopathic neuroendocrine cell hyperplasia |
| **Meningothelial cell line**                    |
| - Minute pulmonary meningothelial-like nodules  |
| **Epithelial cell line**                        |
| - Atypical adenomatous hyperplasia              |
| - Adenocarcinoma in situ                        |

MALT: mucosa-associated lymphoid tissue.
(B-cells), as well as diffuse positivity for CD13, CD79a and BCL2. The infiltrates are negative for CD5 and CD10 staining [6, 7, 19]. The neoplasm can be associated with the presence of MALT-lymphoma-specific genetic aberration, the t(11;18)(q21;q21) resulting in API2/MALT1 fusion transcripts [11, 20].

Given the indolent course of this tumour, immediate treatment following diagnosis may not be indicated. TROCH et al. [11] reported a retrospective study involving 11 patients, all of whom remained untreated after a median follow-up period of 28.1 months. Eventually, three of those patients showed progression and were placed on therapy. Moreover, this untreated group was compared with 10 patients on treatment during the same period. These 10 patients underwent various treatment modalities, and after a median follow-up time of 58 months, one patient from the treated group died. No significant difference was seen in terms of time to progression [11]. AHMED et al. [6] studied 22 patients, 20 of whom were treated. Treatment modalities reported were surgery, chemotherapy with or without rituximab and radiation therapy. The chemotherapy regimens used were CHOP (cyclophosphamide, Adriamycin, vincristine and prednisone), RCD (rituximab, cyclophosphamide and dexamethasone), CVP (cyclophosphamide, vincristine and prednisone) and RF (rituximab and fludarabine). Of those 20 patients, 19 achieved an objective response described as a complete resolution in nine patients and 10 achieving a partial response, while one did not respond [6]. However, the literature shows no clear data on the clinical course of MALT lymphoma when treated versus left untreated, likely related to this tumour being very rare.

**Lymphomatoid granulomatosis**

Lymphomatoid granulomatosis is a rare Epstein–Barr virus (EBV)-associated B-cell lymphoproliferative disorder characterised histologically by the angiocentric and angiodestructive proliferation of atypical lymphoid cells. It tends to spread along the bronchovascular bundles and interlobular septa, often resulting in distortion of the underlying lung architecture. First described by LIEBOW et al. [21] in 1972, these lesions are composed of EBV-positive B-cells surrounded by a reactive T-cell infiltrate [22, 23].

Most patients are middle-aged men with a male to female ratio of 2:1 [21, 24]. Symptomatic patients reported having cough, often productive, dyspnoea and fever. Other symptoms include weight loss, arthralgia and skin lesions. Skin involvement can be in the form of an erythematous macular rash, small plaque-like lesions or indurated subcutaneous lesions predominantly on the extremities [21]. Clinically, the lungs are involved in 100% of the patients, most commonly in the lower lobes, followed by the central nervous system (38%), liver (19%), skin (17%) and kidneys (15%). There is usually no nodal, bone marrow or spleen involvement [24].

The most commonly reported radiographic finding is bilateral nodular opacities in the mid-lower lung zones. The nodules often show angiocentricity and peribronchovascular distribution (figure. 3). Most can progress rapidly, coalesce and may cavitate. Migratory nodules may be seen in some instances, with some of these nodules exhibiting a spontaneous “waxing–waning” course. Other findings include unilateral nodular opacities, ill-defined pulmonary opacities, air bronchograms, thin-walled cysts and hilar lymphadenopathy [18, 21, 25–29].
LEE et al. [29] reviewed imaging studies of five patients with lymphomatoid granulomatosis. The main chest radiograph finding was nodules or masses with poorly defined margins. The number of nodules ranged from one to 19 and size from 1–5 cm. CT chest scans showed bilateral nodules ranging in number from five to >60 with irregular yet well-defined margins. Most nodules were <1 cm, and the largest diameter ranged from 1.3 to 6.5 cm. In one case, magnetic resonance imaging revealed masses with higher intensity signals than muscles on the T1- and T2-weighted images. In addition, a right upper lobe pulmonary artery narrowing caused by a perihilar mass and severe left main pulmonary artery wall thickening resulting in complete occlusion by either thrombosis or the tumour was seen.

Given the nonspecific radiological findings, histology is needed to confirm the diagnosis. Findings include the presence of angiocentric immunoproliferation of well-demarcated, mixed mononuclear cells that have a predilection to infiltrate the lumen and the subintimal regions of medium-sized arteries and veins (figure 4) [21, 25, 29]. Immunohistochemical and in situ hybridisation techniques are used to identify EBV-infected cells, as most cases of lymphomatoid granulomatosis have shown proliferation of EBV-infected large B-cells with a prominent T-cell reaction. The presence of these findings are key features necessary for the diagnosis of lymphomatoid granulomatosis [22, 23, 30, 31]. Lymphomatoid granulomatosis is graded based on the number of EBV-positive large B-cells per high power field: grade 1: <5 positive cells; grade 2: 5–50 cells; and grade 3: >50 positive cells [32, 33].

Treatment of lymphomatoid granulomatosis is guided by the grading, so it is imperative to have an accurate evaluation and diagnosis of the specimens. Interferon-α is used for grade 1 and 2 disease, whereas immunochemotherapy with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab is used for grade 3 disease. The National Cancer Institute performed a prospective trial studying the outcomes in patients following treatment with interferon-α based on the grading. Progression-free survival improved to 56% (median follow-up of 5.1 years) in patients with lymphomatoid granulomatosis grade 1 and 2 and 44% (median follow-up of 32 months) in patients with grade 3 disease [34].

FIGURE 2 Pulmonary extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. a) Diffuse infiltration of a lymphocytic infiltrate of small lymphocytes with scattered follicles (haematoxylin and eosin; 12.5×). b) The lymphoma invades adjacent structures, including airways (arrow), a feature that distinguishes this infiltrate from a benign reactive inflammatory infiltrate (haematoxylin and eosin; 100×). c) The malignant cell population consists of small lymphocytes with clear spaces between adjacent cells, so-called centrocytic-like features. Larger nuclei and plasmacytoid cells may also be seen (haematoxylin and eosin; 400×).

FIGURE 3 Lymphomatoid granulomatosis. Computed tomography scans a) at and b) below the carinal bifurcation level demonstrates multiple bilateral angiocentric and peribronchovascular lung nodules.
PTLD

PTLD occasionally develops in recipients of solid organs and rarely among bone marrow recipients. It usually appears within a year of transplant (1 month to 7 years). The clinical course varies from a benign flu-like illness to potentially life-threatening fulminant disease and mirror pathological features, ranging from benign lymphoid hyperplasia to frank malignant lymphoma. Risk factors for development include EBV seronegativity, concomitant cytomegalovirus infection, allograft type, paediatric age and immunosuppressive regimen. Polyclonal B-cell lymphomas (positive EBV population cell lines) are more common than monoclonal lymphomas in these specimens [35–37]. Extranodal involvement is more common than nodal involvement, and imaging features depend on the organ of involvement. Lung involvement usually manifests as multiple homogeneous solid nodules of varying sizes (figure 5), which may occasionally cavitate. Diffuse involvement of the lungs, pleural thickening and mediastinal lymphadenopathy are other features that may be seen on CT [18, 38].

In the lung, PTLD is usually divided into two categories: polymorphic (low-grade) or monomorphic (high-grade) lesions. The gross morphology of these nodules usually reveals tan/white nodules with necrosis. On histopathology, large lymphoid nodules with pleural invasion may be seen (figure 6a). Polymorphic PTLD consists of small lymphocytes, immunoblasts and plasma cells with low-grade cytological features, which are distinguished from reactive infiltrates by the presence of EBV-positive cells. Monomorphic PTLD consists of lymphoid infiltrates with predominantly large cells with areas of marked cytological atypia and mitoses. Invasion of surrounding structures may be seen (figure 6b) [39, 40].

Reduction of immunosuppression is the cornerstone of therapy. Disease regression in response to decreasing immuno-suppressive regimen is a diagnostic feature. Other treatment modalities include surgical resection of local disease, radiotherapy and medical treatment with interferon-α, antiviral therapy, interleukin-2 infusion and rituximab. The prognosis depends on the pathological grade and cell type with the low-grade polymorphic type behaving more favourably than high-grade PTLD in the lung [41].
DLBCL

DLBCLs that are primary to the lung are unusual. They comprise approximately 10–20% of all pulmonary lymphomas and are seen in patients aged 50–70 years with no sex predisposition [42]. A number of risk factors have been identified, including collagen vascular diseases, immunosuppression, congenital immunodeficiencies and AIDS. Patients usually present with cough, haemoptysis and dyspnoea and may report fever and cachexia.

Imaging studies reveal single or multiple solid nodules or a mass, which commonly cavitates or shows central hypoattenuation (figure 7). Thoracic lymphadenopathy may be present. Tissue diagnosis is needed to confirm the diagnosis. Small biopsies, including cytological specimens, can be diagnostic as the cells have large, malignant vesicular nuclei and high-grade cytological features (figure 8). The cells express a B-cell phenotype (CD20 and CD79a) with scattered reactive T-cells in the background. The morphological features can be similar to carcinoma, melanoma and germ cell tumours. Therefore, immunohistochemical studies and flow cytometric analysis are essential to confirm the diagnosis. Distinguishing a primary pulmonary DLBCL from a mediastinal large B-cell lymphoma extending to the lung is difficult and requires both clinical and imaging findings. Also, since DLBCL may be EBV positive, it should be distinguished from lymphomatoid granulomatosis and the high-grade form of PTLD [42].

Vascular tumours

Epithelioid haemangioendothelioma

Epithelioid haemangioendothelioma is a rare tumour of vascular origin. It was first described by DAIL et al. [43]. WELDON-LINNE [44] confirmed its endothelial lineage by using electron microscopy and immunohistochemical techniques to show diffuse cytoplasmatic staining with factor VIII-related antigen. WEISE et al. [45] coined the term epithelioid haemangioendothelioma based on these findings. It is a low to intermediate grade neoplasm, which can arise in different organ systems, such as the lungs, liver, bone or lymphoid tissue, and sometimes as synchronous primary tumours. Over half of the patients have
symptoms at their initial presentation that are usually related to the size and location of the tumour, including cough, pleuritic chest pain, haemoptysis and shortness of breath [46]. It is more common in females with a mean age of onset between 35 and 44 years, with the majority being diagnosed before the age of 40 years. Life expectancy ranges between 1 and 15 years [47–49]. In one study, the 5-year survival was reported to be 60% [48]. Poor prognostic factors include weight loss, anaemia, pleural haemorrhage and effusion, fibrinous pleuritis, extrapleural proliferation and the presence of spindle tumour cells [47, 48].

Radiographically, it can present as unilateral or bilateral sub-centimetre perivascular nodules, with ill-defined or well-defined margins. Some nodules can grow up to 2 cm in size and can be seen in conjunction with pleural effusions. They are mostly found in relation to small- to medium-sized vessels and bronchi [50]. These findings can lead to an erroneous diagnosis of metastatic disease from another primary site (figure 9). Ground-glass opacities (GGOs) and interlobular septal thickening are other atypical radiological findings [49–51].

The diagnosis is confirmed by tissue sampling via a transbronchial, transthoracic, thoracoscopic or an open lung biopsy. The pathological findings include round to oval shaped nodules with a hypocellular centre and peripheral zones with bland epithelioid cells. The cells may contain intracytoplasmic lumina and can have an extracellular matrix in the surrounding tissue (figure 10). Immunohistochemistry can be positive for multiple vascular-endothelial markers including ERG, CD31, CD34, factor VIII and FLI1 [52–54]. Cytokeratin can be positive in these cells. Recently, translocations involving chromosomal regions 1p36.3 and 3q25 resulting in the formation of a WWTR1-CAMTA1 fusion gene have been discovered in approximately 90% of these cases. A polyclonal antibody to the C-terminus of CAMTA1 has proven to be a useful tool in the diagnosis of this neoplasm [55].

Epithelioid haemangioendothelioma can metastasise after resection, and there is no standardised therapy for epithelioid haemangioendothelioma [56]. Surgical resection for isolated lesions, chemotherapy with

---

**FIGURE 8** Diffuse large B-cell lymphoma. a) Lymphoid nodule with marked necrosis invading bronchovascular area (haematoxylin and eosin; 20×). b) Histological features indistinguishable from high-grade post-transplant lymphoproliferative disorder (haematoxylin and eosin; 200×).

**FIGURE 9 a, b** Epithelioid haemangioendothelioma. Computed tomography lung images demonstrate a) innumerable bilateral perivascular nodules. b) Coronal reformatted soft-tissue images also show multiple hepatic low-density lesions with nodular peripheral enhancement suggesting haemangiomas (arrow).
radiation, immunotherapy for diffusely disseminated metastatic disease and watchful waiting for asymptomatic stable disease are all suggested treatment modalities [52, 57–61].

**Kaposi sarcoma**

Primary Kaposi sarcoma of the lung is extremely rare. Metastasis to the lungs from mucocutaneous or nodal disease is more common. There are four variants, of which the AIDS-related form with CD4 <200 cells·mm$^{-3}$ is most commonly encountered. Human herpes virus (HHV)-8, as well as HIV, are presumed causative factors. The disease can also manifest in post-transplant immunosuppressed patients [62, 63].

Imaging findings include multiple, bilateral and fairly symmetrical, ill-defined, peribronchovascular lung nodules, “flame-shaped” opacities on high-resolution CT with perihilar and lower zone predominance, GGOs, patchy consolidations and interlobular septal thickening (figure 11). Pleural effusion and thoracic lymphadenopathy might also be present [64, 65]. Violaceous lesions can be found in the central airways on bronchoscopic examination [66].

The pathological diagnosis can not only be made by thoracoscopic biopsies, but also by bronchoscopic and transthoracic needle biopsies. The diagnostic features of the lesion include atypical spindle cells with only minimal cytological atypia, intervening “slit-like” vascular spaces containing red blood cells in a “box-car” configuration and scattered plasma cells (figure 12). Immunohistochemical studies reveal the spindle cells are positive for HHV-8 and vascular antibodies including ERG and CD31 [67].

**Angiosarcoma**

Pulmonary angiosarcoma is a rare tumour and is largely metastatic. Thorium dioxide (Thorotrast), used as a radiopaque contrast agent in the 1930s and 1940s and since discontinued, was heavily linked to hepatic angiosarcomas. Polyvinyl chloride is also a risk factor. Primary pulmonary angiosarcomas are considered...
exceedingly rare, and only a handful of cases have been reported. The most common imaging presentation is multiple lung nodules or masses associated with perilesional alveolar haemorrhage, pleural effusions and disseminated disease (figure 13) [68, 69].

Angiosarcomas throughout the body can have spindled and/or epithelioid morphology [70]. The pathological features of angiosarcomas in the lung have a more epithelioid morphology with cells more in clusters and solid nests. The nuclei are usually more vesicular, mimicking carcinomas and mesotheliomas (figure 14). Immunohistochemical studies reveal these epithelioid tumour cells can be cytokeratin positive, making the distinction from nonsmall cell carcinomas difficult. In this scenario, the ample vascular spaces in the background should raise the differential diagnosis of a vascular tumour and immunohistochemical studies for vascular markers (ERG and CD31) will be positive in angiosarcomas and negative in carcinomas.

Neuroendocrine tumours

Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia

Pulmonary neuroendocrine cells are present throughout the pulmonary tree. These cells can proliferate as an adaptive response to hypoxia such as in people living at high-altitudes and patients with underlying chronic lung disease such as emphysema or fibrosis [71]. The term diffuse idiopathic pulmonary neuroendocrine cell hyperplasia (DIPNECH) is given when there is no known predisposing factor for their proliferation [72]. The proliferation of these cells can result in distortion of the lung microstructure, as these cells have the ability to synthesise and release various amines and peptides.

DIPNECH is a rare under-recognised entity. According to the World Health Organization (WHO) classification of lung tumours, it is classified as a pre-invasive lesion within the spectrum of the epithelial neuroendocrine tumours [73]. The term DIPNECH was first used in 1992 by AGUAYO et al. [72], who first described six patients with diffuse hyperplasia of pulmonary neuroendocrine cells. Since none of their cases had any previous lung disease or smoking history, these authors suggested that hyperplasia in these patients was a primary process and the term DIPNECH was used. The majority of patients were middle-aged
nonsmoking females, who present in most instances with nonspecific respiratory symptoms that have been present for years prior to diagnosis. DAVIES et al. [74] reviewed 19 cases; 79% were females and 84% were nonsmokers, with a mean age of 57.5 years. NASSAR et al. [75] reported 25 cases of which 92% were females with a mean age of 58 years, 67% were nonsmokers and 92% were symptomatic (71% had cough, 63% dyspnoea and 25% presented with wheezing). The pulmonary function test analysis showed 54% to have an obstructive pattern, 13% restrictive, 17% mixed obstructive and restrictive, and 17% with a normal pulmonary function test [75]. Diffusion capacity has also been shown to be compromised [72].

CT findings range from normal imaging to multiple bilateral pulmonary nodules (3 mm – 3 cm), GGOs, bronchial wall thickening, bronchiecasis and mosaic attenuation with air-trapping [72, 74–76]. Presence of multiple small lung nodules with heterogeneous mosaicism of the lung parenchyma on routine inspiratory CT chest images and multifocal air-trapping on expiratory high-resolution CT may serve as diagnostic clues to the entity (figure 15).

The diagnosis requires histopathological confirmation, and surgical biopsy is the gold standard. Pathological features include clusters of neuroendocrine cell hyperplasia within the epithelium of the small airways and tumourlets consisting of clusters of neuroendocrine cells ≤5 mm invading through the basement membrane into the subepithelial area. When these clusters are ≥5 mm, they are classified as a carcinoid tumour (figure 16). MARCHEVSKY et al. [77] proposed that "presence of five or more neuroendocrine cells, singly or in clusters located within the basement membrane of the bronchiolar epithelium of at least three bronchioles, combined with three or more carcinoid tumourlets can be used to consistently diagnose DIPNECH on a surgical biopsy".

To date, the treatment strategy is uncertain. Watchful waiting, chemotherapy, inhaled and systemic steroids, bronchodilators, lung resection and lung transplant have been used [72, 74, 75, 78, 79]. AGUAYO
et al. [72] used chemotherapy in two patients, which showed no obvious clinical effect; one patient remained stable for 8 years and one died of respiratory failure.

The general course of the disease is stable, although clinical deterioration and progression to respiratory failure have been described. Thus, treatment should be tailored based on clinical presentation, course of the disease, presence of hypoxia, extent and distribution of the radiological findings and abnormalities of the pulmonary function test.

**Meningothelial tumours**

*Minute pulmonary meningotheial-like nodules*

This is a rare benign neoplasm of the lung of uncertain clinical significance. It never metastasises and can present as solitary or bilateral diffuse nodules. Previously known as chemodectoma because of characteristic microstructure, cytological features and presence adjacent to vessels, it is now known that these nodules contain endocrine granules and resemble meningothelial cells [80–83].

In most cases, the presentation is incidental, and patients are usually asymptomatic. The incidence of such tumours ranges between 0.3% and 9% of all lung resections [84–86]. The incidence was reported to be 7% in one of the largest reports studying 1724 pulmonary resection specimens. A total of 271 minute pulmonary meningotheial-like nodules were identified in 121 patients [86]. Approximately 80% of patients are females with most cases diagnosed in the 5th and 6th decades [83, 86, 87].

These tumours are found in association with lung injury, supporting a reactive rather than neoplastic origin. They are commonly found in patients with congestive heart failure, venous thromboembolism, chronic bronchitis, emphysema and lung cancer, particularly adenocarcinoma [83, 85, 86, 88].

On imaging, these tumours are mostly reported as scattered small nodules or micronodules (<2 mm in size) on CT (figure 17). They can present as solitary nodules or diffuse bilateral ground-glass nodules in a miliary pattern. On occasion, they can have an apical distribution [88]. In another report, it was found that these nodules tend to favour the right lung three times more than the left [83].

Microscopically, these nodules consist of epithelioid cell nests in a "Zellballen"-like arrangement and are located in relation to small veins [89]. The cells are round to oval and widen the alveolar wall (figure 18).

![Diffuse idiopathic neuroendocrine cell hyperplasia](https://doi.org/10.1183/16000617.0142-2019)
On electron microscopy, these cells are connected with very well-formed desmosomes [83]. Immunohistochemical studies show positive staining for progesterone, vimentin and epithelial membrane antigen, which are markers found in meningothelial cells [84, 90].

The clinical significance of this rare, benign non-metastasising tumour is uncertain. Nonetheless, its association with other medical comorbidities should be highlighted and may warrant further workup.

**Epithelial tumours**

*Adenocarcinoma in situ*

Multifocal low-grade primary lung adenocarcinomas can present as multiple GGOs. The spectrum of noninvasive adenocarcinoma includes foci of atypical adenomatous hyperplasia (AAH) that measure ≤5 mm, adenocarcinoma *in situ* (AIS) if the focus measures >5 mm but ≤3 cm in greatest dimension, and minimally invasive adenocarcinoma (MIA) if the focus measures ≤3 cm and has an invasive or solid stromal component <5 mm. This represents a continuum of disease progression for all adenocarcinomas that evolve from GGOs (AAH, AIS and MIA) into solid nodules (invasive adenocarcinoma). Importantly, this progression may arise in multiple foci in the lung and, therefore, represent multiple primary tumours.

Adenocarcinoma *in situ* is a slow-growing, indolent subtype of lung adenocarcinoma. It is characterised by a lepidic, noninvasive, non-metastatic growth pattern. Previously referred to under the banner of "bronchioloalveolar cell carcinoma", this term has now been discontinued, following the International Association for the Study of Lung Cancer/European Respiratory Society/American Thoracic Society recommendations from 2011 [91]. In the WHO classification of lung cancer from 2015, AIS has been categorised in the "preinvasive" category along with AAH [92].

High-resolution CT in AIS reveals pure GGOs <3 cm, usually ranging from 5 to 20 mm [92]. They have a higher attenuation and may be larger than GGOs seen with AAH, which are, by definition, <5 mm. An accurate assessment of these nodules requires thin-slice high-resolution CT with slice-thickness <3 mm.
(ideally 1–1.5 mm), to characterise ground-glass and part-solid components in the nodule [92]. They tend to be solitary and may show only minimal changes on radiographic follow-up. As such, they need long-term follow-up when compared to solid nodules in the lung if surgical resection is deferred (figure 19).

**FIGURE 19** Spectrum of lung adenocarcinoma. a–c) Low-grade, indolent adenocarcinoma. a) Initial high-resolution computed tomography (HRCT) image reveals a 5-mm ground-glass nodule in the left upper lobe that could represent atypical adenomatous hyperplasia or adenocarcinoma in situ (arrow). b) Follow-up HRCT after 5 years demonstrates increase in overall nodule size with a new <5 mm solid component, which suggests progression to minimally invasive adenocarcinoma. c) Fiducial marker was placed prior to surgical resection. d, e) Progression of minimally invasive adenocarcinoma to invasive adenocarcinoma. Note, 27 mm part-solid nodule in the right upper lobe with central <5 mm solid component (arrowhead) suggestive of minimally invasive adenocarcinoma and adjacent subcentimetre ground-glass nodule (arrow) presumed atypical adenomatous hyperplasia or inflammatory (d). e) HRCT at 2 years follow-up shows increase in size and attenuation of the part-solid nodule and growth of its solid stromal component, consistent with progression to invasive adenocarcinoma. The previously seen small, pure ground-glass nodule, which was likely inflammatory, has resolved.

**FIGURE 20** Adenocarcinoma in situ. a) Malignant glandular epithelium present on alveolar surface without evidence of invasion into the underlying lung (haematoxylin and eosin; 12.5×). b) Malignant glandular epithelium characterised by hyperchromatic nuclei with mild to moderate cytological atypia covers the alveolar surface (haematoxylin and eosin; 100×).
AIS is a malignant, pre-invasive malignancy that is further classified into three types: mucinous, non-mucinous and mixed. It tends to arise from the distal airways or alveoli, either from glandular cells or Type 2 pneumocytes. AIS grows along the alveolar septa (“lepidic growth pattern”) and does not invade into the surrounding airspaces, stroma, blood vessels or pleura (figure 20). Patients are usually asymptomatic, and these lesions are identified as incidental nodules on routine imaging.

The incidence of true AIS is thought to be much less due to the more restrictive inclusion criteria proposed by the WHO. The incidence is higher in females, Asians and nonsmokers.

The pathological diagnosis of AIS is a nodule comprised of malignant glandular epithelium with a lepidic growth pattern, ≤3 mm, without evidence of invasion into the surrounding lung. This requires complete excision of the tumour and microscopic examination of the entire nodule to confirm there is no evidence of invasion into the surrounding lung. Hence, a diagnosis of AIS cannot be made with fine-needle aspiration or core biopsy [93].

AIS has an excellent prognosis if completely surgically resected with a cumulative incidence of recurrence of 0% at 5 years [94]. Patients can be followed using radiographic surveillance, though complete surgical excision should be done for definitive treatment.

Role of positron emission tomography imaging in the diagnosis of multiple lung nodules

The American College of Chest Physicians suggests a role for positron emission tomography (PET) in the evaluation of indeterminate lung nodules [95]. It is best suited to characterise indeterminate solid nodules >8 mm in patients with low-to-moderate probability of malignancy [96]. High-risk patients should undergo biopsy and very low-risk patients should undergo CT surveillance. The size of nodules is a major deciding factor for PET and most existing PET scanners have a spatial resolution of 8–10 mm (smaller nodules like minute pulmonary meningothelial-like nodules and DIPNECH may not be detected). Lung adenocarcinoma and carcinoid tend to have low to intermediate uptake, while lymphoproliferative and vascular tumours show high fluorodeoxyglucose (FDG) uptake (PET positive), though FDG uptakes can vary and should not be used as a surrogate for tissue sampling.

Conclusion

Several rare primary lung neoplasms may present as multiple synchronous indeterminate lung nodules on chest CT. These are often not included in the initial differential diagnoses and merit increased awareness among radiologists, pathologists and pulmonologists, as well as a multidisciplinary team approach.

Author contributions: S. Ghosh, A.C. Mehta, S. Abuqayyas, S. Raju and C. Faver contributed to the content of this manuscript and to the approval of the final version to be published.

Conflict of interest: None declared.

References
1. Fiche M, Capron F, Berger F, et al. Primary pulmonary non-Hodgkin’s lymphomas. Histopathology 1995; 26: 529–537.
2. Herbert A, Wright DH, Isaacs PG, et al. Primary malignant lymphoma of the lung: histopathologic and immunologic evaluation of nine cases. Hum Pathol 1984; 15: 415–422.
3. Kurtin PJ, Myers JL, Adlakha H, et al. Pathologic and clinical features of primary pulmonary extranodal marginal zone B-cell lymphoma of MALT type. Am J Surg Pathol 2001; 25: 997–1008.
4. Isaacs PG, Wright DH. Malignant lymphoma of mucosa-associated lymphoid tissue. A distinctive type of B-cell lymphoma. Cancer 1983; 52: 1410–1416.
5. Thieblemont C, Berger F, Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95: 802–806.
6. Ahmed S, Kussick SJ, Siddiqui AK, et al. Bronchial-associated lymphoid tissue lymphoma: a clinical study of a rare disease. Eur J Cancer 2004; 40: 1320–1326.
7. Noguchi S, Yatera K, Kido T, et al. Pulmonary mucosa-associated-lymphoid tissue (MALT) lymphoma with multiple thin-walled pulmonary cysts: a case report and review of the literature. Intern Med 2013; 52: 2325–2329.
8. Li G, Hansmann ML, Zwingers T, et al. Primary lymphomas of the lung: morphological, immunohistochemical and clinical features. Histopathology 1990; 16: 519–531.
9. Cordier J-F, Chaileux E, Lauque D, et al. Primary pulmonary lymphomas: a clinical study of 70 cases in nonimmunocompromised patients. Chest 1993; 103: 201–208.
10. Zinzani PL, Magagnoli M, Galeni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: analysis of 75 patients. J Clin Oncol 1999; 17: 1254–1254.
11. Troch M, Streubel B, Petkov V, et al. Does MALT lymphoma of the lung require immediate treatment? An analysis of 11 untreated cases with long-term follow-up. Anticancer Res 2007; 27: 3633–3637.
12. Cadranel J, Wislez M, Antoine M. Primary pulmonary lymphoma. Eur Respir J 2002; 20: 750–762.
Borhani AA, Hosseinzadeh K, Almusa O, Liebow AA. The J. Burns Amberson Lecture.

Halkos ME, Miller JI, Mann KP, Katzenstein A, Peiper S. Detection of Epstein-Barr virus genomes in lymphomatoid granulomatosis: analysis of 29 cases.

Ding X, Makino T, Koezuka S, Reams BD, McAdams HP, Howell DN, Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis.

Suda T, Chida K, Hayakawa H, Sato A, Hayakawa H, Uchiyama H, Meuwissen HJ, Hussain M. Bronchus-associated lymphoid tissue in human lung: correlation of hyperplasia with tissue with multiple pure ground-glass opacities: a case report. J Cardiotorac Surg 2017; 12: 2.

Streubel B, Simonitsch-Klupp I, Müllauer L, et al. Variable frequencies of MALT lymphoma-associated genetic aberrations in MALT lymphomas of different sites. Leukemia 2004; 18: 1722–1726.

Liebow AA, Carrington CR, Friedman PJ. Lymphomatoid granulomatosis. Hum Pathol 1972; 3: 457–558.

Katzenstein A, Peiper S. Detection of Epstein-Barr virus genomes in lymphomatoid granulomatosis: analysis of 29 cases by the polymerase chain reaction technique. Mod Pathol 1990; 3: 435–441.

Guiney JD, Jaffe E, Kingma D, et al. Pulmonary lymphomatoid granulomatosis. Evidence for a proliferation of Epstein-Barr virus infected B-lymphocytes with a prominent T-cell component and vasculitis. Am J Surg Pathol 1994; 18: 753–764.

Song JY, Pittaluga S, Dunleavy K, et al. Lymphomatoid granulomatosis, a single institute experience: pathologic findings and clinical correlations. Am J Surg Pathol 2015; 39: 141–156.

Liebow AA. The J. Burns Amberson Lecture – Pulmonary Angiitis and Granulomatosis 1–3. Am Rev Respir Dis 1973; 108: 1–18.

Weisbrot IM. Lymphomatoid granulomatosis of the lung, associated with a long history of benign lymphoepithelial lesions of the salivary glands and lymphoid interstitial pneumonitis: report of a case. Am J Clin Pathol 1976; 66: 792–801.

Gibbs A. Lymphomatoid granulomatosis – a condition with affinities to Wegener’s granulomatosis and lymphoma. Thorax 1977; 32: 71–79.

Hicken P, Dobie JC, Frew E. The radiology of lymphomatoid granulomatosis in the lung. Clin Radiol 1979; 30: 661–664.

Lee JS, Tuder R, Lynch DA. Lymphomatoid granulomatosis: radiologic features and pathologic correlations. AJR Am J Roentgenol 2000; 175: 1335–1339.

Colby TV. Current histological diagnosis of lymphomatoid granulomatosis. Mod Pathol 2012; 25: S39–S42.

Swerdlow SH, Campo E, Harris NL, Swerdlow S, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, International Agency for Research on Cancer, 2008.

Pittaluga S, Wilson WH, Jaffe ES. Lymphomatoid granulomatosis. In: Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, International Agency for Research on Cancer, 2008; pp. 247–249.

Dunleavy K, Chatopoulos A, Kawada J, et al. Immune characteristics associated with lymphomatoid granulomatosis and outcome following treatment with interferon-alpha. Blood 2010; 116: 963.

Reams BD, McAdams HP, Howell DN, et al. Posttransplant lymphoproliferative disorder: incidence, presentation, and response to treatment in lung transplant recipients. Chest 2003; 124: 1242–1249.

Halkos ME, Miller JJ, Mann KP, et al. Thoracic presentations of posttransplant lymphoproliferative disorders. Chest 2004; 126: 2013–2020.

Brennan KC, Lowe LH, Yeaney GA. Pediatric central nervous system posttransplant lymphoproliferative disorder. AJNR Am J Neuroradiol 2005; 26: 1695–1697.

Bhoriha AA, Hosseinzadeh K, Almusso O, et al. Malignant imaging of posttransplant lymphoproliferative disorder after solid organ transplantation. Radiographics 2009; 29: 981–1000.

Capello D, Rasi S, Oreste P, et al. Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients. J Pathol 2009; 218: 478–486.

Yin CC, Medeiros LJ, Abruzzo LV, et al. EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient. Am J Clin Pathol 2005; 125: 222–228.

Mohlar I, Keung YK. Treatment of post-transplant lymphoproliferative disorder with rituximab and radiation in a patient with second renal allograft. Nephrol Dial Transplant 2001; 16: 2114–2115.

Kara I, Yildirim F, Berber E, et al. Pulmonary involvement of diffuse large B-cell lymphoma with cavitory lesions. Am J Med Sci Med 2016; 4: 47–49.

Dall DH, Liebow AA, Gmelich JT, et al. Intravascular, bronchiolar, and alveolar tumor of the lung (IVBAT). An analysis of twenty cases of a peculiar sclerosing endothelial tumor. Cancer 1983; 51: 452–464.

Weldon-Linne C, Victor T, Christ M, et al. Angiogenic nature of the “intravascular bronchioloalveolar tumor” of the lung: an electron microscopic study. Arch Pathol Lab Med 1981; 105: 174–179.

Weiss SW, Ishak KG, Dall DH, et al. Epithelioid hemangioendothelioma and related lesions. Semin Diagn Pathol 1986; 3: 259–287.

Amin R, Hiroshima K, Kokubo T, et al. Risk factors and independent predictors of survival in patients with pulmonary epithelioid haemangioendothelioma. Review of the literature and a case report. Respirology 2006; 11: 818–825.

Kitaichi M, Nagai S, Nishimura K, et al. Pulmonary epithelioid hemangioendothelioma in 21 patients, including three with partial spontaneous regression. Eur Respir J 1998; 12: 89–96.

Bagan P, Hassan M, Barthes FLP, et al. Prognostic factors and surgical indications of pulmonary epithelioid hemangioendothelioma: a review of the literature. Ann Thorac Surg 2006; 82: 2010–2013.
Mizutani E, Tsuta K, Maeshima AM, et al. Minute pulmonary meningothelial-like nodules: clinicopathologic analysis of 121 patients. *Hum Pathol* 2009; 40: 678–682.

Dail DH. Uncommon tumors. In: Dail DH, Hammar SP, Colby TV, eds. Pulmonary Pathology – Tumors. New York, Springer, 1995; pp. 157–341.

Gleason JB, Valentin R, Almeida P, et al. Diffuse pulmonary meningotheliomatosis: a literature review of a rare diffuse parenchymal lung disease with unclear clinical significance. *J Assoc Chest Physicians* 2017; 5: 18.

Korn D, Bensch K, Liebow AA, et al. Multiple minute pulmonary tumors resembling chemodectomas. *Am J Pathol* 1960; 37: 641–672.

Pelosi G, Maffini F, Decarli N, et al. Progesterone receptor immunoreactivity in minute meningothelioid nodules of the lung. *Virchows Arch* 2002; 440: 543–546.

Tang Y, He Z, Zhu Q, et al. The 2011 IASLC/ATS/ERS pulmonary adenocarcinoma classification: a landmark in personalized medicine for lung cancer management. *J Thorac Dis* 2014; 6: Suppl. 5, S589–S596.

Kerr KM. Pulmonary adenocarcinomas: classification and reporting. *Histopathology* 2009; 54: 12–27.

Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* 2011; 6: 244–285.

Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2013; 143: Suppl. 5, e93S–e120S.

Ashraf H, Dirksen A, Loft A, et al. Combined use of positron emission tomography and volume doubling time in lung cancer screening with low-dose CT scanning. *Thorax* 2011; 66: 315–319.